How many drugs treat Irritable bowel syndrome?

Drug Landscape tracks 8 marketed treatments for Irritable bowel syndrome (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/irritable-bowel-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Irritable bowel syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irritable bowel syndrome (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Irritable bowel syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Linzess	LINACLOTIDE	AbbVie	Guanylate Cyclase-C Agonist [EPC]	Heat-stable enterotoxin receptor	2012-01-01
Librax	CLIDINIUM	Roche	Anticholinergic	Muscarinic acetylcholine receptor M3	1982-01-01
Chlordiazepoxide Hydrochloride	CHLORDIAZEPOXIDE	Bausch Health	Benzodiazepine	Histamine H1 receptor	1960-01-01
Methylscopolamine	METHSCOPOLAMINE	Fougera Pharms	Anticholinergic	Muscarinic acetylcholine receptor M3	1953-01-01
Bentyl	dicycloverine	Forest Labs Inc	Anticholinergic	Histamine H2 receptor	1950-01-01
Hycodan	METHYLHOMATROPINE	Endo	methylhomatropine		1943-01-01
scopolamin	scopolamin	University Hospital, Angers		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Linzess	Linzess	TriHealth Inc.		Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Irritable bowel syndrome
AbbVie · 1 drug in Irritable bowel syndrome
Bausch Health · 1 drug in Irritable bowel syndrome
Endo · 1 drug in Irritable bowel syndrome
Forest Labs Inc · 1 drug in Irritable bowel syndrome
Fougera Pharms · 1 drug in Irritable bowel syndrome
Roche · 1 drug in Irritable bowel syndrome
TriHealth Inc. · 1 drug in Irritable bowel syndrome
University Hospital, Angers · 1 drug in Irritable bowel syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Irritable bowel syndrome:

Cite this brief

Drug Landscape (2026). Irritable bowel syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/irritable-bowel-syndrome. Accessed 2026-06-10.

Irritable bowel syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing